CHICAGO (AP) – Two popular stop-smoking drugs are as safe for the heart as nicotine patches and dummy pills, according to research requested by U.S. and European regulators.

The results come from an extension of a big study of Chantix and Zyban that earlier found no increased risks for severe psychiatric problems including suicidal behavior. Those findings were reported in 2016.

2. FDA Approves Better Vaccine Against Painful Shingles Virus - Monday, October 23, 2017

U.S. regulators have approved a new, more effective vaccine to prevent painful shingles, which is caused by the chickenpox virus.

Drugmaker GlaxoSmithKline said the Food and Drug Administration approved it late Friday. It will be the second shingles vaccine in the U.S. market. Merck launched the first one in 2006.

3. FDA OKs Glaxo's Inhaler, First One to Combine 3 Medicines - Wednesday, September 20, 2017

The Food and Drug Administration has approved the first inhaler that combines three medicines to ease breathing in patients with emphysema or chronic bronchitis.

The FDA approved sales of GlaxoSmithKline PLC's Trelegy Ellipta (TRELL'-eh-gee ee-LIP'-teh) late Monday.

4. Drugmakers Pledge Restraint, But Prices Will Still Soar - Tuesday, February 28, 2017

TRENTON, N.J. (AP) – Several big drugmakers are trying to quell the ongoing furor over high drug prices by revealing more information about their pricing and even pledging to keep a lid on increases.

5. Memphis Researcher's Strep Vaccine Moves to Trial Phase - Saturday, September 26, 2015

The fight against strep throat is being waged from Memphis.

Memphis-based Vaxent and the Pan-Provincial Vaccine Enterprise Inc., also known as Prevent, have initiated a Phase 1 clinical trial of StreptAnova, a vaccine designed to prevent Group A streptococcal infections. The trial will be conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia.

6. British Drugmaker Cutting Hundreds of US Jobs - Friday, December 5, 2014

TRENTON, N.J. (AP) – Hundreds of British drugmaker GlaxoSmithKline's 17,000 U.S.-based employees will lose their jobs by the end of next year under the pharmaceutical industry's latest restructuring.

7. US Officials Unveil Plan to Test Ebola Drugs - Thursday, November 6, 2014

NEW ORLEANS (AP) – The quest for an Ebola treatment is picking up speed. Federal officials have unveiled a plan to test multiple drugs at once, in an umbrella study with a single comparison group to give fast answers on what works.

8. WHO: Millions of Ebola Vaccine Doses Ready in 2015 - Monday, October 27, 2014

LONDON (AP) — The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

9. AstraZeneca Rejects $119 Billion Offer From Pfizer - Tuesday, May 20, 2014

LONDON (AP) – The board of AstraZeneca on Monday rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that caused a sharp slide in the U.K. company's share price as many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga.

10. Democrats Push for Mississippi State Employee Pay Raise - Friday, February 21, 2014

JACKSON, Miss. (AP) – Democrats say they'll keep trying to give all Mississippi government employees at least a $1,000 pay raise in the coming year, even after several attempts were blocked Wednesday in the Republican-majority House.

11. FDA Overturns Safety Limits on Diabetes Drug - Tuesday, November 26, 2013

WASHINGTON (AP) – The Food and Drug Administration is lifting severe safety restrictions on the former blockbuster diabetes pill Avandia, citing recent data suggesting that the much-debated medication does not increase the risk of heart attack.

12. Pfizer to Pay $491 Million to Resolve Drug Marketing Case - Wednesday, July 31, 2013

The U.S. Justice Department said Tuesday that drugmaker Pfizer Inc. will pay almost $491 million to resolve an investigation into illegal marketing of the organ transplant drug Rapamune by a company Pfizer later acquired.

13. 10 Drugmakers Team Up to Improve Testing Process - Thursday, September 20, 2012

TRENTON, N.J. (AP) – Pharmaceutical industry heavyweights are teaming up to address a challenge that's long vexed drugmakers: how to improve the way experimental drugs are tested so they can get approved, and reach patients, faster.

14. Tenn. to Receive $13M in Glaxo Settlement - Wednesday, July 4, 2012

Tennessee Attorney General Bob Cooper says the state will receive more than $13 million as part of a settlement agreement with GlaxoSmithKline PLC over illegal marketing and drug pricing allegations.

15. GlaxoSmithKline to Pay $3 Billion for Health Fraud - Tuesday, July 3, 2012

WASHINGTON (AP) – GlaxoSmithKline LLC will pay $3 billion and plead guilty to promoting two popular drugs for unapproved uses and to failing to disclose important safety information on a third in the largest health care fraud settlement in U.S. history, the Justice Department said Monday.

16. High Court Says No OT Pay for Drug Sales Reps - Tuesday, June 19, 2012

The Supreme Court has ruled that sales representatives for pharmaceutical companies do not qualify for overtime pay under federal law, a big victory for the drug industry.

In a 5-4 decision Monday, June 18, the court’s conservative majority concluded that the roughly 90,000 people who try to persuade doctors to prescribe certain drugs to their patients are not covered by the federal law governing overtime pay.

17. GSK-Leased Warehouse Financed for $10.2M - Monday, January 16, 2012

Bank of America NA has granted a $10.2 million loan to five affiliates of Exeter Property Group for a warehouse at 4480 Swinnea Road leased to GlaxoSmithKline Consumer Healthcare LP.

18. Court to Look at Overtime Pay for Drug Sales Reps - Tuesday, November 29, 2011

WASHINGTON (AP) – The Supreme Court has agreed to consider whether pharmaceutical sales representatives can bill their employers for overtime, a case that could affect the pay of tens of thousands of people.

19. Internet Minders OK Vast Expansion of Domain Names - Tuesday, June 21, 2011

SINGAPORE (AP) – Internet minders voted Monday to allow virtually unlimited new domain names based on themes as varied as company brands, entertainment and political causes, in the system's biggest shake-up since it started 26 years ago.

20. GSK Announces Plans to Sell Memphis Plant - Friday, April 15, 2011

Pharmaceutical giant GlaxoSmithKline Thursday announced plans to sell its manufacturing site at 2149 Harbor Ave. in Memphis, where products made include over-the-counter pain relievers Goody’s and BC Powder.

21. GSK Announces Plans to Sell Memphis Plant - Thursday, April 14, 2011

Pharmaceutical giant GlaxoSmithKline Thursday announced plans to sell its manufacturing site at 2149 Harbor Ave. in Memphis, where products made include over-the-counter pain relievers Goody’s and BC Powder.

22. Senate Bill Aims to Combat Pharmaceutical Theft - Wednesday, March 9, 2011

WASHINGTON (AP) – Law enforcement officials would have more leeway to pursue and punish criminals who steal prescription pharmaceuticals under a proposal introduced Tuesday by Senate lawmakers.

23. GlaxoSmithKline Settles Bad Drug Case for $750M - Thursday, October 28, 2010

BOSTON (AP) — British pharmaceutical company GlaxoSmithKline PLC will pay $750 million to settle allegations it knowingly manufactured and sold adulterated drugs, including the antidepressant Paxil, federal prosecutors in Massachusetts said.

24. GlaxoSmithKline Launches Free Vaccine Program - Wednesday, March 31, 2010

British drugmaker GlaxoSmithKline is launching a program in the U.S. to provide free vaccines to adults who don’t have health insurance.

The company, which has a facility on Presidents Island, said the program will include shots for hepatitis A and B, tetanus, diptheria and whooping cough. A cervical cancer vaccine also will be available for women.

25. GlaxoSmithKline Launches Free Vaccine Program - Tuesday, March 30, 2010

NEW YORK (AP) - British drugmaker GlaxoSmithKline PLC reported Monday it is launching a program in the U.S. to provide free vaccines to adults who don't have health insurance.

GlaxoSmithKline, which has a facility in Memphis, said the program will cover low-income adults who meet eligibility requirements. The free vaccines include shots for hepatitis A and B, tetanus, diphtheria and whooping cough. The company's cervical cancer vaccine Cervarix also will be included for women between the ages of 19 and 25.

26. FDA Drug Approvals Mostly Flat in 2009 - Thursday, January 7, 2010

WASHINGTON (AP) - New drugs cleared by the U.S. Food and Drug Administration last year kept pace with 2008, suggesting a much-touted push for drug safety has not slowed down approvals.

The FDA's new leaders did step up early warnings about potential drug safety issues and citations to companies that violate safety regulations.

27. Vaccines on Horizon for AIDS, Alzheimer's, Herpes - Wednesday, November 18, 2009

MARIETTA, Pa. (AP) - Malaria. Tuberculosis. Alzheimer's disease. AIDS. Pandemic flu. Genital herpes. Urinary tract infections. Grass allergies. Traveler's diarrhea. You name it, the pharmaceutical industry is working on a vaccine to prevent it.

28. GlaxoSmithKline Third-Quarter Profit Up 11 Percent - Thursday, October 29, 2009

LONDON (AP) - GlaxoSmithKline PLC, the world's second largest drug maker by revenue, forecast a big boost from its swine flu vaccines before the end of the year as it reported an 11 percent rise in third quarter earnings on Wednesday.

29. Glaxo Gets FDA Approval for Leukemia Drug - Wednesday, October 28, 2009

NEW YORK (AP) - GlaxoSmithKline PLC received FDA approval for its drug Arzerra as a treatment for chronic lymphocytic leukemia, a slowly progressing cancer of the blood and bone marrow.

The FDA said in a statement Monday that the approval applies to patients who have already received other forms of chemotherapy, which are no longer effective at controlling the condition.

30. Glaxo Seasonal Flu Vaccine Approved for Children - Wednesday, October 21, 2009

NEW YORK (AP) - GlaxoSmithKline PLC said Monday the Food and Drug Administration approved the seasonal flu vaccine Fluarix for children.

The drug had already been approved for adults. It is now also approved for children between the ages of 3 years and 17 years old.

31. GlaxoSmithKline Changes Doctor Training Policy - Tuesday, September 22, 2009

TRENTON, N.J. (AP) - British drugmaker GlaxoSmithKline PLC said Monday it is making major changes in its funding of educational programs for doctors, reducing the number it sponsors and switching its focus to independent ones with balanced information.

32. FDA Panel Backs Glaxo's Cervical Vaccine for Women - Thursday, September 10, 2009

WASHINGTON (AP) - Federal health officials said Wednesday a long-delayed vaccine from GlaxoSmithKline successfully blocks the leading virus that causes cervical cancer in women.

The U.S. Food and Drug Administration's vaccine panel voted overwhelmingly that the vaccine Cervarix appears safe and effective for girls and women ages 10 to 25.

33. FDA Says Glaxo Vaccine Blocks Cancer-Causing Virus - Tuesday, September 8, 2009

WASHINGTON (AP) - A vaccine from GlaxoSmithKline successfully blocks the virus that causes most cases of cervical cancer, the Food and Drug Administration said Friday.

In documents posted online, the FDA said Cervarix – Glaxo's vaccine against human papilloma virus or HPV – successfully blocked the two most cancerous strains of the virus nearly 93 percent of the time.

34. FDA Approves GlaxoSmithKline's Hiberix Vaccine - Friday, August 21, 2009

NEW YORK (AP) - Drugmaker GlaxoSmithKline PLC said Thursday it received U.S. Food and Drug Administration approval for its vaccine Hiberix, a booster shot that helps prevent a bacterial infection.

35. FDA Scrutinizes Infection Risk with Amgen Drug - Wednesday, August 12, 2009

WASHINGTON (AP) - Federal health officials are questioning increased infection rates and tumors seen with an osteoporosis drug from Amgen that analysts say is key to the company's growth.

The U.S. Food and Drug Administration said Tuesday that patients taking Amgen Inc.'s denosumab were more likely to develop infections of the skin, ear and urinary tract than patients taking placebo.

36. Ranbaxy Gets Final FDA OK for Generic Glaxo Drug - Wednesday, August 12, 2009

NEW YORK (AP) - Generic drugmaker Ranbaxy Laboratories Ltd. said Tuesday its U.S. subsidiary received final U.S. Food and Drug Administration approval on two generic doses of the migraine drug Imitrex.

37. Glaxo Buys Nabi Staph Infection Vaccine for $46M - Monday, August 10, 2009

NEW YORK (AP) - Nabi Biopharmaceuticals said Thursday it sold its staph infection vaccine PentaStaph to British drugmaker GlaxoSmithKline PLC in a deal worth as much as $46 million.

Nabi said it will receive $20 million upfront, with the rest of the payments depending on four undisclosed milestones being accomplished. It said it expects the sale to close by the end of the year, and said it believes it will complete the four milestones within 18 months.

38. Drug Industry, Pfizer Lead in Health Lobbying - Wednesday, July 22, 2009

WASHINGTON (AP) - The drug industry's trade group and one of the nation's biggest pharmaceutical companies reported spending more money than other health care organizations on lobbying in the second quarter of this year.

39. FDA Requires Chantix, Zyban to Have Warning - Thursday, July 2, 2009

NEW YORK (AP) - The U.S. Food and Drug Administration will require two smoking-cessation drugs, Chantix and Zyban, to carry the agency's strongest safety warning over side effects including depression and suicidal thoughts.

40. FDA: More Data Needed on Glaxo Nausea Drug - Thursday, June 25, 2009

TRENTON, N.J. (AP) - The U.S. Food and Drug Administration has rejected GlaxoSmithKline PLC's application to approve an experimental drug for nausea and vomiting, saying more data is needed.

41. GlaxoSmithKline Gets Inflammatory Disease Partner - Wednesday, June 24, 2009

NEW YORK (AP) - British drug developer GlaxoSmithKline PLC said Tuesday it is collaborating with Chroma Therapeutics Ltd. to develop treatments for inflammatory disorders.

Chroma has the potential to receive $1 billion in milestone and option payments if all four programs under the deal are successful. The partnership will focus on using Chroma's technology to target specific cells at the root of inflammatory diseases such as rheumatoid arthritis.

42. Drugmakers Rush to Produce a Swine Flu Vaccine - Monday, June 15, 2009

LONDON (AP) - With swine flu now an official pandemic, the race is on among drugmakers to produce a vaccine.

GlaxoSmithKline said Thursday after the World Health Organization declared a global flu epidemic that it would be ready within weeks to begin large-scale vaccine production. Sanofi-Aventis also said it had started working on its own version. On Friday, Swiss pharma giant Novartis announced it had created an experimental vaccine that has not been tested in people. Novartis' vaccine was made via a cell-based technology that may prove faster than the traditional way of making vaccines, which relies on chicken eggs.

43. Dodd's Wife Serves on Health Care Company Boards - Monday, June 15, 2009

WASHINGTON (AP) - The wife of a senator playing a lead role on a national health care overhaul sits on the boards of four health care companies, one of several examples of lawmakers with ties to the medical industry.

44. Glaxo Signs Deal With Concert on Early Stage Drugs - Wednesday, June 3, 2009

LONDON (AP) - GlaxoSmithKline PLC signed a potential $1 billion deal with U.S. biotech company Concert Pharmaceuticals on Tuesday to access deuterium-containing medicines, a deal that will beef up its pipeline of early stage drugs.

45. Glaxo, Genmab Cancer Drug Gets FDA Panel Nod - Monday, June 1, 2009

NEW YORK (AP) - GlaxoSmithKline PLC and its development partner Genmab came one step closer Friday to gaining approval on their cancer treatment Arzerra after an advisory panel recommended the Food and Drug Administration approve the therapy.

46. Nations Urge WHO to Change Swine Flu Assessment - Tuesday, May 19, 2009

GENEVA (AP) - China, Britain, Japan and other countries urged the World Health Organization on Monday to be very cautious about declaring the arrival of a swine flu pandemic, fearing that a premature announcement could cause worldwide panic and confusion. WHO bent to their wishes.

47. GlaxoSmithKline Taking Pandemic Vaccine Orders - Monday, May 18, 2009

LONDON (AP) - Pharmaceutical giant GlaxoSmithKline said Friday it has received orders from several countries to stockpile pandemic vaccine as soon as it gets the vaccine's key ingredient from the World Health Organization.

48. WHO Meets on Production of Swine Flu Vaccine - Friday, May 15, 2009

GENEVA (AP) As swine flu cases topped 6,600 worldwide, vaccine makers and other experts met Thursday at the World Health Organization to discuss the tough decisions that must be made quickly to fight the evolving virus.

49. US FDA Approves Dissolvable Version of Lamictal - Tuesday, May 12, 2009

LONDON (AP) - The U.S. Food and Drug Administration has approved a dissolvable version of GlaxoSmithKline PLC's blockbuster drug Lamictal, the company said Monday.

Lamictal, or lamotrigine, is prescribed for the treatment of epilepsy or bipolar disorders. The company said a dissolvable version, which disintegrates on the patient's tongue, is important because people with those disorders can have a hard time swallowing pills.

50. Glaxo Sells US Wellbutrin Rights to Biovail - Thursday, May 7, 2009

LONDON (AP) - GlaxoSmithKline PLC said Wednesday it is selling full commercial rights to antidepressant Wellbutrin XL in the United States to Canadian drug developer Biovail Corp. for $510 million.

51. Swine Flu Casts Shadow Over Economy - Tuesday, April 28, 2009

LONDON (AP) - Uncertainty over the swine flu outbreak cast a shadow over the struggling global economy Monday, raising fears that that the spread of the virus could harm trade and tourism and undermine businesses just as they begin to rally.

52. Glaxo Buys Stiefel Laboratories for $2.9 Billion - Tuesday, April 21, 2009

LONDON (AP) - British drug maker GlaxoSmithKline PLC said Monday it will pay $2.9 billion to buy American dermatology business Stiefel Laboratories Inc. – the latest deal in a flurry of mergers and acquisitions in the pharmaceuticals industry.

53. Report: Pharma Deals in Q1 Exceed All 2008 Deals - Tuesday, April 21, 2009

TRENTON, N.J. (AP) - The burst of drugmaker mergers announced in the first quarter is worth nearly 50 percent more than all the industry deals announced in 2008, according to a new report.

Deals in the quarter had a combined value of $166 billion, more than 10 times the value of deals announced in last year's first quarter and well over the $114 billion in deals announced in all of 2008.

54. Glaxo and Pfizer Create New HIV Drug Company - Monday, April 20, 2009

TRENTON, N.J. (AP) - Pharmaceutical giants GlaxoSmithKline PLC and Pfizer Inc. will pool resources to create a new company to develop and sell HIV medicines, leveraging a small investment into the No. 2 market position.

55. GlaxoSmithKline Seeks New Approval for Breast Drug - Thursday, April 2, 2009

TRENTON, N.J. (AP) - GlaxoSmithKline PLC on Wednesday applied for approval in the U.S. and Europe to sell an existing breast-cancer drug as a first-line treatment.

The British pharmaceutical company's Tykerb was approved here two years ago as part of a treatment for most women with advanced breast cancer that wasn't stopped after chemotherapy and other drugs. It's also been approved for that use in the 27 European Union countries and several others.

56. GlaxoSmithKline Reduces Stake in Quest - Monday, March 23, 2009

NEW YORK (AP) - GlaxoSmithKline PLC said Friday that it sold approximately 5.7 million shares of Quest Diagnostics Inc. for more than $250 million, reducing its stake to about 16.5 percent.

57. Report: Glaxo to Cut Prices for Poor Countries - Tuesday, February 17, 2009

NEW YORK (AP) - Drug maker GlaxoSmithKline PLC says it will cut drug prices to the 50 poorest countries in the world and use 20 percent of its profits from those countries to build health clinics and other infrastructure, according to published reports.

58. Report: Glaxo in Talks to Buy Indian Generic Maker - Monday, February 9, 2009

NEW YORK (AP) - U.K. drug developer GlaxoSmithKline PLC is reportedly in talks to buy Indian generic drug developer Piramal Healthcare Ltd. for about $1.5 billion.

Late Friday, the Wall Street Journal reported that people familiar with the potential deal said the companies are at an early stage of talks. GlaxoSmithKline said it would not comment, and Piramal could not be reached for comment.

59. GlaxoSmithKline Opening Huge Eastern Vaccine Plant - Friday, January 9, 2009

MARIETTA, Pa. (AP) - British drugmaker GlaxoSmithKline PLC is moving to expand its vaccine business in the key U.S. market by opening a sprawling East Coast vaccine factory, with production targeted to begin in April.

60. Glaxo and Dynavax Sign Development Deal - Thursday, December 18, 2008

LONDON (AP) - British drug maker GlaxoSmithKline PLC said Wednesday it will pay U.S. biotechnology company Dynavax Technologies Corp. $10 million upfront in a research deal to develop drugs to treat autoimmune and inflammatory diseases.

61. FDA Approves Adult Use of Glaxo Vaccine Boostrix - Tuesday, December 9, 2008

NEW YORK (AP) - U.S. regulators have approved the vaccine Boostrix for use in adults, GlaxoSmithKline PLC said Monday.

The U.K.-based drugmaker GlaxoSmithKline has a facility on Presidents Island in Memphis.

62. GlaxoSmithKline Plans UK Plant Closure, Job Cuts - Wednesday, November 12, 2008

LONDON (AP) - British drug maker GlaxoSmithKline PLC said Tuesday it is planning to close one of its English plants, which employs 620 people, by 2013 because the majority of drugs made at the plant are losing their patent protection and facing generic competition within a year.

63. Vanishing Jobs, Stressed Consumers Feed Downturn - Monday, November 10, 2008

WASHINGTON (AP) - The nation's unemployment rate is at a 14-year high, General Motors reported a massive third-quarter loss and says it may run out of cash next year, and Ford is planning more job cuts after burning through billions of its own.

64. Report: US Drug Sales Growth Heads Toward New Low - Thursday, October 30, 2008

WASHINGTON (AP) - U.S. sales of pharmaceuticals will grow at the slowest rate on record this year, as the weakening economy compounds other factors hampering the industry, according to a report issued Wednesday.

65. Diabetes Drug Costs Soaring, Top $12B Last Year - Wednesday, October 29, 2008

CHICAGO (AP) - Americans with diabetes nearly doubled their spending on drugs for the disease in just six years, with the bill last year climbing to an eye-popping $12.5 billion.

Newer, more costly drugs are driving the increase, said researchers, despite a lack of strong evidence for the new drugs' greater benefits and safety. And there are more people being treated for diabetes.

66. Head of North American Ops Departs GlaxoSmithKline - Tuesday, September 9, 2008

LONDON (AP) - GlaxoSmithKline PLC said Monday that the president of its North American pharmaceutical division will leave the company Dec. 1.

Chris Viehbacher will also step down from his position on the company's board of directors effective immediately.

67. Dillard Door Named Top 100 Security Integrator - Thursday, July 17, 2008

Memphis-based Dillard Door & Security Inc. has been named one of the Top 100 Security System Integrators in the United States, according to Security Distribution and Marketing Magazine.

This is the third time the company, which was ranked 80 out of 100, has been named to the list.

68. No End in Sight: Housing in Freefall Until Credit Loosens and Supply Recedes, Experts Say - Thursday, February 28, 2008

NEW YORK (AP) - House prices may still have a long way to fall.

Across much of the nation, home values are dropping - even those backed by solid mortgages - and banks are repossessing more every day. Most experts say the dive won't hit bottom for another year and only after excess inventory is sharply reduced and credit markets improve.

69. $5M GlaxoSmithKline Expansion Not Expected to Bring Jobs - Thursday, January 31, 2008

GlaxoSmithKline (GSK) is embarking on a $5 million expansion and upgrade to its Presidents Island facility, and while it won't mean new jobs in Memphis, the investment is nonetheless a boon for the local economy.

70. GSK Files $5M PermitFor Production Line Change - Tuesday, January 29, 2008
     GlaxoSmithKline has filed a $5 million permit with the city-county Department of Construction Code Enforcement for its facility at 2149 Harbor Ave. on Presidents Island. The facility is adding new filling and packaging l

71. Archived Article - Tuesday, July 24, 2007

5015 Citation Drive
Memphis, TN 38118
Sale Amount: $19.3 million

Sale Date: June 27, 2007

Buyer: Distribution I TL Owner LLC

72. Relationships, Client Needs Behind Husch Eppenberger Offshoot - Thursday, January 18, 2007

Jennifer Ziegenhorn is not from Memphis, but after more than 13 years practicing law here, says she is beginning to feel very much at home in the Bluff City.

Ziegenhorn moved to Memphis right after graduating from law school at the University of Arkansas-Fayetteville in 1993.Ziegenhorn recently was promoted to equity partner of the Memphis office of Husch & Eppenberger LLC. She also will head the firm's commercial litigation and dispute resolution group.

73. Dillard Door GarnersNational Recognition - Friday, July 28, 2006
     Dillard Door & Security Inc. has been recognized as one of the top 100 security integration companies in the United States, according to a report released by Pennsylvania-based Security Distribution & Marketing Magazine.

74. Archived Article: Comm Briefs - Friday, February 14, 2003
Baptist Memorial Health Care and Goldsmith's present the second Women's Heart Sunday event from 1 p

Baptist Memorial Health Care and Goldsmith's present the second Women's Heart Sunday event from 1 p.m. to 4 p.m. Sunday at four Memphis-area Golds...

75. Archived Article: Tech Focus - Wednesday, May 15, 2002
State leaps forward in biotechnology surge State leaps forward in biotechnology surge By Sharon H. Fitzgerald Special to the Daily News Building a new industrial sector isnt a job states tackle often, but thats exactly what Tennessee is doing.This e...